Clinical Trials Logo

Meningococcal Disease clinical trials

View clinical trials related to Meningococcal Disease.

Filter by:

NCT ID: NCT00944034 Completed - Clinical trials for Meningococcal Disease

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

Start date: July 2009
Phase: Phase 2/Phase 3
Study type: Interventional

This extension study V72P12E1 will investigate the safety, tolerability and immunogenicity of a fourth (booster) dose of rMenB+OMV NZ at 12, 18 and 24 months of age in subjects previously primed with rMenB+OMV NZ according to two different three-dose immunization schedules in infancy (2, 4 and 6 or 2, 3 and 4 months of age in the parent study V72P12). The study will also explore the bactericidal antibody persistence at 12, 18 and 24 months of age, following the two different immunization schedules, in order to identify the optimal timing for boosting. Two catch-up rMenB+OMV NZ doses will be given to unprimed, naïve toddlers at 12 (subjects enrolled in the control group of V72P12), 18 and 24 months of age (two new cohort of subjects enrolled). These subjects will generate data for assessing the safety and immunogenicity of a two-dose catch-up regimen at these ages, but will also serve as controls for a descriptive comparison of antibody persistence and booster responses for the other groups.

NCT ID: NCT00847145 Completed - Clinical trials for Meningococcal Disease

Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

Start date: February 2009
Phase: Phase 3
Study type: Interventional

The proposed study is an Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers

NCT ID: NCT00728260 Completed - Meningitis Clinical Trials

36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds

Start date: July 2005
Phase: N/A
Study type: Observational

To further characterize the safety profile of Menactra vaccine and to identify any signals of potentially vaccine-related adverse events (AEs) not detected during pre-licensure studies.

NCT ID: NCT00661713 Completed - Clinical trials for Meningococcal Disease

Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

Start date: June 2008
Phase: Phase 2/Phase 3
Study type: Interventional

The proposed study is aimed to assess the antibody response and short-term persistence of Novartis Meningococcal B Vaccine after one, two or three doses and to evaluate the optimal vaccination schedule in an adolescent population.

NCT ID: NCT00601731 Completed - Clinical trials for Meningococcal Disease

Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months

Start date: February 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate how well the immuno response against meningococcal serogroups A, C, W and Y lasts in children who were vaccinated with MenACWY as infants.

NCT ID: NCT00560313 Completed - Clinical trials for Meningococcal Disease

Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

Start date: July 2007
Phase: Phase 2
Study type: Interventional

This study is aimed to evaluate safety, tolerability and immunogenicity of three doses of Novartis 4CMenB and of one dose of Novartis Meningococcal ACWY vaccine when administered to healthy at-risk adults.

NCT ID: NCT00488683 Completed - Clinical trials for Meningococcal Disease

B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants

Start date: July 2007
Phase: Phase 2
Study type: Interventional

This study is aimed to assess whether the frequency of meningococcal serogroup A, C, W-135 and Y specific memory B Cells, measured 1 month after a primary vaccination series of Novartis MenACWY vaccine, predicts the specific serum bactericidal activity using human complement (hSBA) of (respectively) serogroup A, C, W-135 and Y at 12 months of age

NCT ID: NCT00433914 Completed - Clinical trials for Meningococcal Disease

Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

Start date: February 2007
Phase: Phase 2
Study type: Interventional

To explore safety, Tolerability and immunogenicity of two formulations of a Meningococcal B Recombinant Vaccine when administered to healthy infants.

NCT ID: NCT00329901 Completed - Clinical trials for Meningococcal Disease

Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years

Start date: April 2006
Phase: Phase 3
Study type: Interventional

Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years

NCT ID: NCT00329849 Completed - Clinical trials for Meningococcal Disease

Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age

Start date: May 2006
Phase: Phase 3
Study type: Interventional

Safety and immunogenicity of meningococcal ACWY conjugate versus polysaccharide vaccine in children 2 to 10 years of age